Evaluation of efficacy of an intralesional injection of Candida antigen in the treatment of molluscum contagiosum

Gamil, Hend; Gharib, Khaled; Essmat, Dina

doi:10.1097/01.ewx.0000516171.71159.fc

Cited by 6 publications

(18 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One study found a significant difference between Candida and saline placebo in complete resolution (50% vs 0%, P < .001) and in partial resolution (25% vs 12.5%, P < .001). 7 In all studies no serious side effects were reported, however some patients experienced localized erythema or edema. Of note, some patients were receiving simultaneous liquid nitrogen therapy.…”

Section: Intralesional Candida Antigenmentioning

confidence: 86%

“…Three studies of intralesional Candida antigen therapy for MC in pediatric patients report a complete response rate between 50% and 56% with no recurrence. [5][6][7] Across the studies, a total of 0.3 mL of Candida antigen was injected into 1-3 lesions in 2-6 week intervals ( Figure 2).…”

Section: Intralesional Candida Antigenmentioning

confidence: 99%

“…14 While treatment was successful, further investigations are necessary to assess efficacy due to the limited number of studies available. Studies of Candida and PPD in pediatric patients showed a complete response rate of 50%-56% [5][6][7] and 85%, 10 respectively. Interferon α was effective at the injected lesion site, however there was no impact on distant lesions and patients with more competent immune systems showed better response.…”

Section: Intralesional Immunotherapy In Immunosuppressed Adultsmentioning

confidence: 99%

“…No recurrence was seen in all patients who completely responded to Candida, MMR vaccine, OK-432, and vitamin D3. [6][7][8][9]11,13,14 Intralesional PPD and interferon α may be an inferior choice in preventing recurrences. 10,12 Patients who had complete resolution of lesions following intralesional therapy had previously failed treatment with imiquimod, with cryotherapy, which could bias the results and overestimate the effectiveness of the treatment.…”

Section: Intralesional Immunotherapy In Immunosuppressed Adultsmentioning

confidence: 99%

“…10,12 Patients who had complete resolution of lesions following intralesional therapy had previously failed treatment with imiquimod, with cryotherapy, which could bias the results and overestimate the effectiveness of the treatment. [5][6][7] There is more robust data reporting good efficacy of intralesional therapy in warts, however more studies are needed to further validate effectiveness in MC.…”

Section: Intralesional Immunotherapy In Immunosuppressed Adultsmentioning

confidence: 99%

See 4 more Smart Citations

Intralesional immunotherapy for molluscum contagiosum: A review

Wells

Saikaly

Schoch

2020

Dermatologic Therapy

View full text Add to dashboard Cite

Molluscum contagiosum (MC) is a common cutaneous viral infection with no standard treatment. The virus responsible for MC is thought to be cleared by cell mediated immunity (CMI). Intralesional immunotherapy that stimulates CMI has been shown to be an effective treatment for other cutaneous viruses. In this review, we evaluate the efficacy and safety of intralesional immunotherapy in the treatment of MC. Articles met inclusion criteria if they examined the effects of intralesional immunotherapy as a treatment for MC, with a clear outcome and reproducible methodology. 228 studies were screened and 10 studies met criteria for inclusion. Intralesional immunotherapies investigated included candida, combined measles, mumps, rubella vaccine, tuberculin purified protein derivative, vitamin D3, inter

show abstract

Section: Intralesional Candida Antigenmentioning

confidence: 86%

Section: Intralesional Candida Antigenmentioning

confidence: 99%

Section: Intralesional Immunotherapy In Immunosuppressed Adultsmentioning

confidence: 99%

Section: Intralesional Immunotherapy In Immunosuppressed Adultsmentioning

confidence: 99%

Section: Intralesional Immunotherapy In Immunosuppressed Adultsmentioning

confidence: 99%

See 3 more Smart Citations

Intralesional immunotherapy for molluscum contagiosum: A review

Wells

Saikaly

Schoch

2020

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

Intralesional injection of tuberculin purified protein derivative (PPD) versus measles, mumps, and rubella (MMR) vaccine in treatment of molluscum contagiosum: a comparative study

Zaky,

Atallah,

Mohyeldeen

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Molluscum contagiosum (MC) is a skin and mucous membrane infection caused by the molluscum virus (MCV). To evaluate safety and efficacy of intralesional injection of tuberculin purified protein derivative (PPD) antigen injection versus MMR (mumps, measles, rubella) antigen for the treatment of molluscum contagiosum (MC). A total of thirty clinically confirmed patients of molluscum were recruited for this trial. Patients who were divided into three groups (A, B and C). Each group consisted of (30) patients. Group (A) subjects received intralesional MMR injections, group (B) subjects received intralesional PPD injection and group (C) received intralesional saline injection. The results of the present study revealed complete clearance of the injected lesions in 12 patients (80%), partial response in 3 patients (20%) of group (A). In group (B), complete clearance of the treated warts was observed in 11 patients (73.3%) and partial response in 4 (26.7%) of patients. In group (C), the majority of patients 8 (53.3%) demonstrated no response while 7 (46.7%) patients showed only partial clearance. We established a good safety and efficacy profile for tuberculin PPD and MMR antigens in treatment of molluscum contagiosum.

show abstract

Comparative efficacy of treatments for molluscum contagiosum: A systematic review and network meta‐analysis

Chao

Tsai

et al. 2023

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Summary Background and objectives Various interventions have been applied to treat molluscum contagiosum, but benefits and efficacy remain unclear. To assess the comparative efficacy and safety of interventions for molluscum contagiosum, a network meta‐analysis was performed. Patients and methods Embase, PubMed, and the Cochrane Library were searched for articles published between January 1, 1990, and November 31, 2020. Eligible studies were randomized clinical trials (RCTs) of interventions in immunocompetent children and adults with genital/non‐genital molluscum contagiosum lesions. Results Twelve interventions from 25 RCTs including 2,123 participants were assessed. Compared with the placebo, ingenol mebutate had the most significant effect on complete clearance (odds ratio [OR] 117.42, 95% confidence interval [CI] 6.37–2164.88), followed by cryotherapy (OR 16.81, 95% CI 4.13–68.54), podophyllotoxin (OR 10.24, 95% CI 3.36–31.21), and potassium hydroxide (KOH) (OR 10.02, 95% CI 4.64–21.64). Data on adverse effects were too scarce for quantitative synthesis. Conclusions Ingenol mebutate, cryotherapy, podophyllotoxin, and KOH were more effective than the other interventions in achieving complete clearance, but safety concerns regarding ingenol mebutate have recently been reported. Due to the possibility of spontaneous resolution, observation is also justified for asymptomatic infection. Factors including adverse effects, cost, patient preference, and medical accessibility should be considered.

show abstract

Evaluation of efficacy of an intralesional injection of Candida antigen in the treatment of molluscum contagiosum

Cited by 6 publications

References 8 publications

Intralesional immunotherapy for molluscum contagiosum: A review

Intralesional immunotherapy for molluscum contagiosum: A review

Intralesional injection of tuberculin purified protein derivative (PPD) versus measles, mumps, and rubella (MMR) vaccine in treatment of molluscum contagiosum: a comparative study

Comparative efficacy of treatments for molluscum contagiosum: A systematic review and network meta‐analysis

Contact Info

Product

Resources

About